ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL

AbbVie and Roche have been fielding their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep chronic lymphocytic leukemia from returning after therapy ends. The companies now think they have some compelling answers.